NASDAQ:MRTX - Mirati Therapeutics, Inc.
$86.63
 $1.08
+1.26%
4:00PM EDT
2019-09-16
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  MRTX     avg for
industry  
  avg for
sector  
42 stocks weight:  93. 41   0. 00   0. 00  
42 stocks rank:  2. 79 K 1. 97 K 1. 30 K
# analyst opinions:  13. 00   12. 84   12. 97  
mean recommendation:  2. 10   2. 12   2. 07  

quick ratio:  17. 35   5. 11   1. 92  
current ratio:  17. 57   5. 50   2. 45  

target price low:  68. 00   79. 53   109. 66  
target price avg:  108. 77   100. 11   131. 81  
target price high:  130. 00   126. 46   149. 31  
1-yr high:  109. 60   104. 28   134. 46  
last close:  86. 53   77. 07   117. 08  
50-day avg:  93. 95   79. 01   117. 12  
200-day avg:  75. 24   81. 51   113. 76  
1-yr low:  32. 32   62. 18   93. 76  
volume:  568. 99 K 2. 53 M 3. 04 M
50-day avg volume:  468. 35 K 3. 41 M 4. 09 M
200-day avg volume:  643. 97 K 3. 18 M 4. 63 M

1-day return:  -0. 14 % -0. 17 % 0. 18 %
this week return:  1. 15 % 0. 31 % 0. 77 %
12-wk return:  -15. 99 % -0. 76 % 2. 99 %
52-wk return:  54. 86 % -5. 78 % 4. 64 %

enterprise value (EV):  2. 87 B 44. 28 B 112. 94 B
market cap:  3. 40 B 500. 31 B 4. 95 T
EBITDA:  -148. 82 M 4. 78 B 7. 74 B
enterprise multiple (EV/EBITDA):  -19. 31   2. 41   10. 42  
enterprise/revenue (EV/R):  544. 17   150. 10   22. 18  
total revenue:  5. 28 M 10. 73 B 31. 64 B
total debt:  200. 00 K 11. 92 B 16. 97 B
debt/equity:  0. 04   244. 15   141. 17  
net income (common):  -142. 45 M 1. 86 B 3. 90 B

shares outstanding:  39. 30 M 579. 09 M 1. 27 B
shares:  23. 88 M 584. 68 M 1. 22 B
shares short:  4. 58 M 16. 45 M 13. 52 M
shares short prior month:  5. 98 M 15. 17 M 12. 50 M
short ratio:  10. 08   6. 82   3. 68  
short % of float:  21. 09 % 7. 00 % 2. 78 %
total cash/share:  12. 44   10. 27   8. 82  
total cash:  488. 77 M 6. 23 B 5. 99 B
free cash flow:  -55. 80 M 2. 91 B 4. 78 B
operating cash flow:  -113. 92 M 4. 10 B 5. 77 B

book value:  12. 26   13. 01   26. 68  
price/book:  7. 06   -9. 86   6. 12  
gross profits:  12. 93 M 8. 13 B 35. 94 B
operating margins:  -2822. 16 % -1246. 94 % -202. 61 %
EBITDA margins:  0. 00 % 7. 07 % 24. 32 %
profit margins:  0. 00 % 3. 12 % 14. 56 %
gross margins:  100. 00 % 44. 41 % 58. 52 %

1-yr max volatility:  31. 37 % --- ---
1-yr mean volatility:  2. 97 % 1. 19 % 0. 86 %

1-yr EPS:  -4. 18   1. 30   4. 02  
forward EPS:  -5. 58   3. 42   6. 65  
P/E:  -20. 68   15. 96   23. 91  
forward P/E:  -15. 33   -4. 28   12. 40  
PE/G:  7. 25   1. 02   -1. 71  
growth:  -2. 85 % 218. 69 % 102. 21 %
earnings high:  -1. 14   1. 22   1. 61  
earnings avg:  -1. 25   0. 85   1. 50  
earnings low:  -1. 40   0. 55   1. 39  
revenue high:  4. 00 M 2. 88 B 8. 82 B
revenue avg:  500. 00 K 2. 80 B 8. 66 B
revenue low:  -0. 00   2. 75 B 8. 48 B
return on assets:  -24. 30 % -2. 87 % 5. 55 %
return on equity:  -39. 63 % -28. 69 % 20. 45 %
revenue/share:  0. 15   13. 15   52. 14  

beta (1yr vs S&P500):  1. 76   1. 20   0. 87  
sharpe (1yr):  0. 99   -0. 09   0. 48  

held % insiders:  0. 92 % 6. 78 % 3. 59 %
held % institutions:  110. 78 % 76. 29 % 67. 25 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-09-16 : MRTX
.    145.419 =         145.419 :: --> INITIAL WEIGHT <--
.                               --> FUNDAMENTALS <--
.    x 0.965 =         140.399 :: P/E factor
.    x 0.945 =         132.687 :: PE/G factor
.    x 1.587 =         210.587 :: beta factor
.    x 0.998 =         210.223 :: sharpe factor
.    x 0.924 =         194.165 :: current ratio factor
.    x 0.868 =         168.526 :: quick ratio factor
.     x 1.06 =         178.672 :: short ratio factor
.    x 0.881 =         157.477 :: EV/R factor
.    x 1.083 =          170.58 :: price-to-book factor
.    x 2.803 =         478.185 :: debt-to-revenue factor
.    x 2.291 =        1095.609 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.037 =        2232.285 :: sector+industry 1-year gains factor
.    x 0.979 =        2184.597 :: industry 12-weeks return factor
.    x 1.315 =        2873.578 :: industry 2-weeks return factor
.    x 1.565 =        4496.395 :: company one-year gains+dividend factor
.    x 3.728 =       16760.557 :: company 13 weeks' performance factor
.    x 1.244 =       20844.933 :: 5-day avg > 200-day avg
.    x 1.249 =       26031.133 :: 50-day avg > 200-day avg
.    x 0.988 =       25723.524 :: "drift" penalty 1 days ago
.      x 1.0 =       25719.293 :: "drift" penalty 4 days ago
.    x 3.831 =       98517.809 :: overall "drift" factor
.    x 0.925 =       91148.343 :: largest single-day price delta factor
.    x 0.996 =       90768.178 :: volatility factor
.    x 0.997 =       90451.529 :: 42-day volatility factor
.    x 2.186 =      197724.803 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.865 =      171083.402 :: forward P/E factor
.    x 1.183 =      202411.406 :: industry recommendation factor
.    x 2.076 =      420252.766 :: company recommendation factor
.    x 1.006 =      422976.983 :: factor historical industry gain for week 37
.    x 0.973 =      411414.508 :: target low factor
.    x 1.169 =      480939.731 :: target mean factor
.     x 1.03 =      495256.711 :: target high factor
.   x 10.443 =     5171946.156 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =          47.688 :: reduced for readability
.   + 45.724 =          93.412 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     93.412 :: FINAL WEIGHT for NASDAQ:MRTX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org